COVID-19 and Multisystem Inflammatory Syndrome in Children (MIS-C) Risk / World Health Organization (WHO)

This study is a multicenter, international, non interventional, retrospective study about SARS-CoV-2 and Multisystem Inflammatory Syndrome (MIS-C) reinfection risk in children.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Sars-CoV-2 Infection COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases MIS-C Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

1 day–18 year

Sex eligibility

All sexes

Study type

Observational

Primary location

ACTIV

Créteil, 94000, France

About this study

This study is based to data collection of cases (patients with MIS-C) compare to controls (patients with SARS-CoV-2 infection) occurring between 01 sep 2021 and 30 apr 2022. For this study cases and controls group will be matched for analyses.

The main of this study is to evaluate the difference of risk of occurrence of MIS-C between a first SARS-CoV-2 infection and a reinfection with SARS-CoV-2.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

group 1: cases

Patients with MIS-C (following SARS CoV-2 infection)
Hospitalised between the 01 sep 2021 and 30 apr 2022
Under 18 years of age
Not vaccinated for SARS-CoV-2

group 2: controls

Patients not hospitalised, treated by outpatient care
With documented SARS-CoV-2 infection between the 01 sep 2021 and 30 apr 2022
Matched with a case on age (+/- 6 months), gender and country
Not vaccinated for SARS-CoV-2

Exclusion criteria

Refusal to participate by patient relative or legal representative

Treatment and study plan

Primary outcomes

proportion of MIS-C cases occurred after first SARS-CoV-2 infection

Time frame: 8 months

Assessment of risk of MIS-C after first SARS-CoV-2 infection
proportion of MIS-C cases occurred after SARS-CoV-2 reinfection

Time frame: 8 months

Assessment of risk of MIS-C after SARS-CoV-2 reinfection
Proportion of SARS-CoV-2 reinfection after first SARS-CoV-2 infection

Time frame: 8 months

Assessment of risk of SARS-CoV-2 reinfection after first SARS-CoV-2 infection

Sponsors and collaborators

Lead sponsor

Association Clinique Thérapeutique Infantile du val de Marne

Other

Registry information

Official study title

SARS-COV-2 (virus Responsible of COVID-19) Reinfection and Multisystem Inflammatory Syndrome in Children (MIS-C) Risk: Matched Case-control Study

Acronym: REPI

Important dates

Study start: 2023
Primary completion: 2024
Study completion: 2024
First posted: Feb 13, 2024
Registry last updated: Nov 21, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed